Juilee Rege1, Jessie Hoxie1, Chia-Jen Liu2, Morgan N Cash3, James M Luther4, Lan Gellert5, Adina F Turcu6, Tobias Else6, Thomas J Giordano2,7,8, Aaron M Udager2,7,8, William E Rainey1,6, Kazutaka Nanba1,9. 1. Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan 48109, USA. 2. Department of Pathology, University of Michigan, Ann Arbor, Michigan 48109, USA. 3. University of Kentucky College of Medicine, Lexington, Kentucky, USA. 4. Division of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA. 5. Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA. 6. Division of Metabolism, Endocrinology, and Diabetes, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, USA. 7. Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan 48109, USA. 8. Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan 48109, USA. 9. Department of Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan.
Abstract
CONTEXT: Somatic gene mutations have been identified in only about half of cortisol-producing adenomas (CPAs). Affected genes include PRKACA, GNAS, PRKAR1A, and CTNNB1. OBJECTIVE: This work aims to expand our understanding of the prevalence of somatic mutations in CPAs from patients with overt Cushing syndrome (OCS) and "subclinical" mild autonomous cortisol excess (MACE), with an immunohistochemistry (IHC)‒guided targeted amplicon sequencing approach using formalin-fixed paraffin-embedded (FFPE) tissue. METHODS: We analyzed FFPE adrenal tissue from 77 patients (n = 12 men, 65 women) with either OCS (n = 32) or MACE (n = 45). Using IHC for 17α-hydroxylase/17,20-lyase (CYP17A1) and 3β-hydroxysteroid dehydrogenase (HSD3B2), we identified 78 CPAs (32 OCS CPAs and 46 MACE CPAs). Genomic DNA was isolated from the FFPE CPAs and subjected to targeted amplicon sequencing for identification of somatic mutations. RESULTS: Somatic mutations were identified in 71.8% (56/78) of the CPAs. While PRKACA was the most frequently mutated gene in OCS CPAs (14/32, 43.8%), somatic genetic aberrations in CTNNB1 occurred in 56.5% (26/46) of the MACE CPAs. Most GNAS mutations were observed in MACE CPAs (5/7, 71.4%). No mutations were observed in PRKAR1A. In addition to the known mutations, we identified one previously unreported mutation in PRKACA. Two patients with MACE harbored 2 adjacent tumors within the same adrenal gland - one patient had 2 CPAs, and the other patient had a CPA and an aldosterone-producing adenoma (identified by IHC for aldosterone synthase). CONCLUSION: A comprehensive FFPE IHC-guided gene-targeted sequencing approach identified somatic mutations in 71.8% of the CPAs. OCS CPAs demonstrated a distinct mutation profile compared to MACE CPAs.
CONTEXT: Somatic gene mutations have been identified in only about half of cortisol-producing adenomas (CPAs). Affected genes include PRKACA, GNAS, PRKAR1A, and CTNNB1. OBJECTIVE: This work aims to expand our understanding of the prevalence of somatic mutations in CPAs from patients with overt Cushing syndrome (OCS) and "subclinical" mild autonomous cortisol excess (MACE), with an immunohistochemistry (IHC)‒guided targeted amplicon sequencing approach using formalin-fixed paraffin-embedded (FFPE) tissue. METHODS: We analyzed FFPE adrenal tissue from 77 patients (n = 12 men, 65 women) with either OCS (n = 32) or MACE (n = 45). Using IHC for 17α-hydroxylase/17,20-lyase (CYP17A1) and 3β-hydroxysteroid dehydrogenase (HSD3B2), we identified 78 CPAs (32 OCS CPAs and 46 MACE CPAs). Genomic DNA was isolated from the FFPE CPAs and subjected to targeted amplicon sequencing for identification of somatic mutations. RESULTS: Somatic mutations were identified in 71.8% (56/78) of the CPAs. While PRKACA was the most frequently mutated gene in OCS CPAs (14/32, 43.8%), somatic genetic aberrations in CTNNB1 occurred in 56.5% (26/46) of the MACE CPAs. Most GNAS mutations were observed in MACE CPAs (5/7, 71.4%). No mutations were observed in PRKAR1A. In addition to the known mutations, we identified one previously unreported mutation in PRKACA. Two patients with MACE harbored 2 adjacent tumors within the same adrenal gland - one patient had 2 CPAs, and the other patient had a CPA and an aldosterone-producing adenoma (identified by IHC for aldosterone synthase). CONCLUSION: A comprehensive FFPE IHC-guided gene-targeted sequencing approach identified somatic mutations in 71.8% of the CPAs. OCS CPAs demonstrated a distinct mutation profile compared to MACE CPAs.
Authors: Kazutaka Nanba; Amy R Blinder; Juilee Rege; Namita G Hattangady; Tobias Else; Chia-Jen Liu; Scott A Tomlins; Pankaj Vats; Chandan Kumar-Sinha; Thomas J Giordano; William E Rainey Journal: Hypertension Date: 2020-01-27 Impact factor: 10.190
Authors: Kazutaka Nanba; Andrew X Chen; Kei Omata; Michelle Vinco; Thomas J Giordano; Tobias Else; Gary D Hammer; Scott A Tomlins; William E Rainey Journal: J Clin Endocrinol Metab Date: 2016-01-14 Impact factor: 5.958
Authors: Junhua Zhou; Elena A B Azizan; Claudia P Cabrera; Fabio L Fernandes-Rosa; Sheerazed Boulkroun; Giulia Argentesi; Emily Cottrell; Laurence Amar; Xilin Wu; Sam O'Toole; Emily Goodchild; Alison Marker; Russell Senanayake; Sumedha Garg; Tobias Åkerström; Samuel Backman; Suzanne Jordan; Satyamaanasa Polubothu; Daniel M Berney; Anna Gluck; Kate E Lines; Rajesh V Thakker; Antoinette Tuthill; Caroline Joyce; Juan Pablo Kaski; Fiona E Karet Frankl; Lou A Metherell; Ada E D Teo; Mark Gurnell; Laila Parvanta; William M Drake; Eva Wozniak; David Klinzing; Jyn Ling Kuan; Zenia Tiang; Celso E Gomez Sanchez; Per Hellman; Roger S Y Foo; Charles A Mein; Veronica A Kinsler; Peyman Björklund; Helen L Storr; Maria-Christina Zennaro; Morris J Brown Journal: Nat Genet Date: 2021-08-12 Impact factor: 41.307
Authors: Gerald Goh; Ute I Scholl; James M Healy; Murim Choi; Manju L Prasad; Carol Nelson-Williams; John W Kunstman; John W Kuntsman; Reju Korah; Anna-Carinna Suttorp; Dimo Dietrich; Matthias Haase; Holger S Willenberg; Peter Stålberg; Per Hellman; Göran Akerström; Peyman Björklund; Tobias Carling; Richard P Lifton Journal: Nat Genet Date: 2014-04-20 Impact factor: 38.330
Authors: Martina Tetti; Siyuan Gong; Franco Veglio; Martin Reincke; Tracy Ann Williams Journal: Front Endocrinol (Lausanne) Date: 2022-08-08 Impact factor: 6.055